NIKKEI 225
38,596.07 -36.95 (-0.10%) HANG SENG
18,065.85 -269.47 (-1.47%) CRUDE OIL
82.34 +0.17 (+0.21%) GOLD FUTURES
2,378.50 +9.50 (+0.40%) DOW
39,134.76 +299.90 (+0.77%) Bitcoin GBP
50,985.63 -741.11 (-1.43%)
APLS Jan 2025 30.000 call
| Previous close | 15.98 |
| Open | 15.98 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 30.00 |
| Expiry date | 2025-01-17 |
| Day's range | 15.98 - 15.98 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Simply Wall St.Investors might be losing patience for Apellis Pharmaceuticals' (NASDAQ:APLS) increasing losses, as stock sheds 6.3% over the past week
While Apellis Pharmaceuticals, Inc. ( NASDAQ:APLS ) shareholders are probably generally happy, the stock hasn't had...
ZacksApellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.
GlobeNewswireSYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
SYFOVRE is the only approved GA treatment to demonstrate a visual function benefit in a prespecified endpointData presented at the Clinical Trials at the Summit Meeting WALTHAM, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that SYFOVRE® (pegcetacoplan injection) preserved visual function at 36 months in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). These positive data from the GALE long-term ext
